



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

April 28, 2022

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol – Biocon

Subject: Press Release on financial results for the quarter and year ended March 31, 2022.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled “**Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9%; Biosimilars Up 48% at Rs 982 Cr; Generics Up 26% at Rs 717 Cr; Research Services Up 15% at Rs 758 Cr.**” pertaining to the audited consolidated financial results of Biocon Limited for the quarter and year ended March 31, 2022.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank



Mayank Verma
Company Secretary & Compliance Officer

Enclosed: Press Release and Fact Sheet

PRESS RELEASE

**Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%;
Core EBITDA at Rs 815 Cr, Up 37% ;
PBT(before Exceptional Items) at Rs 384 Cr, Up 9%**

*Biosimilars Up 48% at Rs 982 Cr; Generics Up 26% at Rs 717 Cr;
Research Services Up 15% at Rs 758 Cr.*

**FY22 Revenue at Rs 8,397 Cr, Up 14%; Core EBITDA Up 18% at Rs 2,669 Cr;
PBT (before Exceptional Item) at Rs 1094 Cr, Up 4%**

Bengaluru, Karnataka, India: April 28, 2022:

Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fourth quarter and the fiscal year ended March 31, 2022.

Commenting on the results, **Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics**, said:

“FY22 was a transformational year for Biocon. Key strategic moves in our Biosimilars business position us for long-term growth and value creation for our stakeholders.

“We believe that the two strategic transactions, with Viatrix and Serum Institute Life Sciences, will position Biocon Biologics as a world leading, unique, fully integrated biologics company with a strong differentiated portfolio of biosimilars and vaccines.

“We reported a strong consolidated revenue growth of 21% for Q4FY22 at Rs 2,476 Crore driven by 48% growth in Biosimilars, 26% in Generics and 15% in Research Services, businesses. Our Gross R&D spends increased by 70% this quarter to Rs 232 Crore reflecting our advancing pipeline, that will drive our future growth. Core EBITDA was up by 37% at Rs 815 Crore, representing healthy operating margins of 33%. PBT before Exceptional Items stood at Rs 384 Crore, up by 9%.

“On a full- year basis, we delivered consolidated revenue of US\$ 1.1 billion (Rs 8,397 Crore) and reported a Core EBITDA growth of 18% at Rs 2,669 Crore with Core EBITDA margins at 32%.”

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q4 and Full Year FY22

In Rs Crore

Particulars	Q4FY22	Q4FY21	Change	FY22	FY21	Change
INCOME						
Generics	717	570	26%	2,341	2,363	-1%
Biosimilars	982	664	48%	3,464	2,800	24%
Novel Biologics	12	11	17%	51	11	386%
Research services	758	659	15%	2,604	2,184	19%
Inter-segment	(61)	(61)	0%	(276)	(215)	29%
Revenue from operations #	2,409	1,842	31%	8,184	7,143	15%
Other income	67	205	-67%	213	255	-16%
Total Revenue	2,476	2,048	21%	8,397	7,398	14%
EBITDA	659	641	3%	2,183	1,907	14%
PBT before Exceptional Items	384	353	9%	1,094	1,055	4%
Net Profit before Exceptional Items	262	257	2%	722	744	-3%
Net Profit for the Period	239	253	-6%	648	740	-12%
R&D Expenses in P&L	191	127	50%	595	553	8%
Gross R&D Spend	232	136	70%	711	627	13%
EBITDA Margins	27%	31%		26%	26%	
Core EBITDA	815	594	37%	2,669	2,270	18%
Core EBITDA* Margins	33%	32%		32%	31%	
Net Profit Margin before Exceptional Items	11%	13%		9%	10%	

#Includes Licensing income. Figures above are rounded off to the nearest Crore; % based on absolute numbers.

*Core EBITDA is EBITDA net of licensing, forex, gain on dilution in Bicara, mark-to-market loss on investments and R&D expense.

PERFORMANCE REVIEW: Q4FY22

- **Consolidated Revenue** grew **21%** to **Rs 2,476 Crore** from Rs 2,048 Crore in Q4FY21
- **EBITDA** was at **Rs 659 Crore** (vs. Rs 641 Crore in Q4FY21) **Up 3 %**
- **EBITDA Margins** were at **27%** (vs. 31% in Q4FY21)
- **Core EBITDA** was **Rs 815 Crore** (vs. Rs 594 Crore in Q4FY21) **Up 37%**
- **Core EBITDA* margins** were at **33%** (vs. 32% in Q4FY21)
- **PBT before Exceptional Items** was **Rs 384 Crore** (vs. Rs 353 Crore in Q4FY21) **Up by 9%**
- **Net Profit before Exceptional Items** was **Rs 262 Crore** (vs. Rs 257 Crore in Q4FY21) **Up 2%**
- **Net Profit[#]** was **Rs 239 Crore** (vs. Rs 253 Crore in Q4FY21)

PERFORMANCE REVIEW: FY22

- **Consolidated Revenue** grew **14%** to **Rs 8,397 Crore** from Rs 7,398 Crore in FY21
- **FY22 EBITDA** was **Rs 2,183 Crore** (vs. Rs 1,907 Crore in FY21) **Up 14%**
- **FY22 EBITDA Margins** were at **26%**
- **FY22 Core EBITDA** was **Rs 2669 Crore** (vs. Rs 2270 Crore in Q4FY21) **Up 18%**
- **FY22 Core EBITDA* margins** were at **32%** (vs. 31% in FY21)
- **FY22 PBT before Exceptional Items** was **Rs 1094 Crore** (vs. Rs 1055 Crore in FY21) **Up 4%**
- **FY22 Net Profit before Exceptional Items** was **Rs 722 Crore** (vs. Rs 744 Crore in FY21)
- **FY22 Net Profit[#]** at **Rs 648 Crore** (vs. Rs 740 Crore in FY21)

*#Adjusted for dilution on Bicara, Mark-to-market loss on investments and exceptional items, **Net Profit grew by 145% and 23%** for the quarter and full year respectively.*

CORPORATE UPDATES

Biocon Limited : Board Announcements:

- **Naina Lal Kidwai joins Biocon Limited Board as Additional Director**

Naina Lal Kidwai, an accomplished banker and business leader, has been appointed as Additional Director on the Board of Biocon Limited, with effect from April 28, 2022 for a period of three years till the conclusion of 47th AGM to be held in 2025.

Ms Kidwai serves as an Additional Director and Senior Advisor for Rothschild India, and Senior Advisor Advent International. She also serves as Non-Executive Director on the boards of many reputed companies like Holcim, Max Financial Services etc. She retired in 2015 as Chairman of HSBC India & Executive Director of HSBC Asia Pacific.

Dividend for FY22

The Board of Directors has recommended a final dividend at the rate of 10% of the face value per share, for the financial year ended March 31, 2022.

BUSINESS SEGMENT REVIEW: Q4FY22

GENERICS: APIs & Generic Formulations

- Q4FY22 Revenue at Rs 717 Crore, Up 26% YoY

FULL YEAR FY22

- FY22 Revenue at Rs 2,341 Crore

Commenting on the Generics segment performance, **Siddharth Mittal, CEO & Managing Director, Biocon Limited**, said, *“The business saw robust sequential as well as YoY growth in Q4, on the back of contributions from new product launches in the U.S., particularly Everolimus, an uptick in our API business and a normalization of supply challenges that impacted us in the first half of the fiscal.*

However, our FY22 performance was muted, largely due to supply and operational challenges earlier in the year, as well as headwinds in the form of pricing pressures, and escalating costs of solvents, raw material and logistics.

As we progress on our mission of providing high quality affordable medicines to patients around the globe, we will continue to focus on expediting our product pipeline, operationalizing new capacities, and accelerating projects that drive cost and operational efficiencies across the organization.

We will also commence work on important new projects in the current fiscal – a large scale synthetic facility in Hyderabad and an injectable facility in Bangalore; as well as expand our fermentation capacities in Bangalore, all of which will provide further impetus to our future growth.”

Business Performance

We received U.S. FDA approvals for Posaconazole, a vertically integrated anti-fungal drug and Dorzolamide, an ophthalmic product, both of which were launched during the quarter.

Our statin formulations portfolio in the U.S. held on to their market share, despite intense pricing pressure. We commenced our first MoW market supply of Tacrolimus capsules to Mexico.

We received our first approval in Singapore for Tacrolimus and in the UAE for Rosuvastatin and Tacrolimus. We also received Marketing Authorization (MA) for Everolimus tablets in Netherlands and Spain.

We received a ‘Compliant’ rating from Health Canada for a remote assessment conducted during the third quarter for our API manufacturing facility in Bangalore.

Our greenfield immunosuppressant API facility in Vizag remains on track with qualification and validation activities planned in FY23.

As a part of our sustainability initiative, we aim to increase the share of our renewable energy consumption through a combination of wind and solar power. Towards this objective, we commenced sourcing solar power during the quarter to add to the wind power.

BIOSIMILARS: Biocon Biologics Limited

Q4FY22

- **Revenue at Rs 982 Crore, Up 48% YoY**
- **Core EBITDA* at Rs 382 Crore, Up 78% YoY**
- **Core EBITDA* margins at 39%**
- **EBITDA at Rs 257 Crore, Up 56% YoY**
- **EBITDA margin at 26%**
- **PBT before exceptional items at Rs 144 Crore**
- **Net R&D Expenses at Rs 112 Crore, representing 11% of revenue**

Full Year FY22

- **Revenue at Rs 3,464 Crore, Up 24% YoY**
- **Core EBITDA* at Rs 1,320 Crore, Up 30% YoY**
- **Core EBITDA* margins at 39%**
- **EBITDA at Rs 1,013 Crore, Up 35% YoY**
- **EBITDA margin at 29%**
- **PBT before exceptional items at Rs 543 Crore**
- **Net R&D Expenses at Rs 310 Crore, representing 9% of revenue**

*(*Core EBITDA is EBITDA net of licensing, forex, mark- to- market loss on investments and R&D expense.)*

Highlights:

- Signed a **definitive agreement to acquire partner Viatris Inc.'s global biosimilars business** for up to **USD 3.335 billion in cash and stock**, creating a unique, global, fully integrated biosimilars leader.
- **Won a 3-year, USD 90 million (MYR 370+ million) contract** from the Ministry of Health, Malaysia to supply Insugen (rh-Insulin).
- Commercialized key biosimilars in several advanced markets, such as **bGlargine in Germany** and **bPegfilgrastim in Italy**.
- Received approval for **bGlargine** from **Health Canada**.
- Partner Celerity Pharmaceuticals received positive EU CHMP opinion for **Inpremia**, a ready-to-use insulin for IV infusion, which uses **Biocon Biologics' human insulin drug substance**.

- Advanced two unpartnered **Wave 2 molecules into the clinic** backed by strong analytical similarity package.
- **Patients reached: 5.3 million** (MAT March 2022)^{##}

Commenting on the performance, Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd. said:

“The 48% (Y-o-Y) growth in revenues this quarter was a result of improved performance across developed and emerging markets, driven by strong market share gains of our interchangeable bGlargine in the USA. The health of our operational and business performance is reflected in the Core EBITDA margins being at 39% of revenues and growing 78% Y-o-Y.

We have progressed well in the development of several next wave biosimilar programs, with two of our molecules entering the clinic. Whilst net R&D was at 9% of revenues in FY22, we expect this to ramp up in FY23 commensurate with the progress of our rich and diverse pipeline which provides Biocon Biologics a sustainable growth opportunity in the years ahead. The two strategic transactions with Serum and Viartis announced in FY22, upon likely closure in the second half of calendar year 2022, will propel us on our path to be a leading vertically integrated biosimilars company globally and will also support the higher investments in developing our pipeline.”

Business Performance: Biocon Biologics

Q4FY22

Revenue for Q4FY22 stood at **Rs 982 Crore**, reporting a growth of **48% YoY**, driven by strong market share gains of Glargine in the U.S. and a robust performance of our commercial portfolio across multiple regions including India. **EBITDA** at **Rs 257 Crore**, was **up 56%**, and **EBITDA margin** stood at **26%**. Core EBITDA margin increased to **39%** for the quarter from 33% in Q4FY21, demonstrating improved operational profitability of the business. **Profit Before Tax**, before exceptional items, stood at **Rs 144 Crore**, up **109%** year-on-year. Our Malaysia operations turned profitable this quarter.

Full Year FY22

Revenue for the full year stood at **Rs 3,464 Crore**, reporting a growth of **24%**, surpassing the growth of 21% witnessed in FY21. There was a significant improvement in profitability at all levels in FY22. **EBITDA** for the year stood at **Rs 1,013 Crore**, a year-on-year growth of **35%**. **Core EBITDA** grew by **30%** and **Profit Before Tax** before exceptional items, grew by **49%** year-on-year. Net R&D spend for the year was at **9%** of revenue. The growth in profits is driven by higher revenues and improved margins.

The two strategic transactions with Serum Institute Life Sciences (SILS) and Viartis announced in FY22 are progressing towards various regulatory approvals. The deals are expected to close in the second half of calendar year 2022.

Developed Markets

In Q4FY22, the developed markets business reported a strong growth, led primarily by **interchangeable bGlargine** (Semglee), as well as improved sales of **bTrastuzumab** (Ogivri) and **bPegfilgrastim** (Fulphila). Additionally, **bGlargine** was commercialized in Germany and received approval in **Canada**, while **bPegfilgrastim** was introduced in Italy.

In the EU, our oncology biosimilars **bPegfilgrastim** (Fulphila) and **bTrastuzumab** (Ogivri) are gradually improving market shares and **bBevacizumab** (Abevmy) has been commercialized in select EU markets this year.

Emerging Markets

During the quarter, Biocon Biologics-led commercial business recorded robust growth on the back of strong performance of key biosimilars in the AFMET and LATAM regions, as well as good business execution in India.

The **Branded Formulations – India** business reported double-digit growth for the quarter. The good performance came on the back of significant ramp-up in prescriptions for **Basalog** (bGlargine), improved patient acquisition and key account penetrations for oncology biosimilars such as **CANMAb** (bTrastuzumab) and **KRABEVA** (bBevacizumab), targeted engagement with HCPs and judicious use of both digital and physical marketing channels.

More recently, the Company's Malaysia subsidiary has won a 3-year tender worth **USD 90 million (MYR 370+ million)** by the **Ministry of Health, Malaysia** for the supply of **Insugen (rh-Insulin)** products. This contract allows Biocon Sdn to consolidate its market leadership in insulins in Malaysia, one of its Top 5 Emerging Markets, where diabetes patients have been benefiting from the company's products since 2016.

The Company continues to see strong demand for its products in existing markets, and expects a greater play in emerging markets post integration of the biosimilars business of Viatriis.

Development Updates

During the year, Biocon Biologics made good progress on the development path of several biosimilar programs for the advanced markets. The Company also initiated clinical trials for two of its unpartnered assets, bDenosumab and bUstekinumab.

Biocon Biologics to Acquire Viatriis' Global Biosimilars Business

Biocon Biologics has taken a transformational step towards its long-term strategy to create a unique, fully integrated, world leading biosimilars enterprise by acquiring partner Viatriis' global biosimilars business for up to USD 3.335 billion in cash and stock.

The combination of two businesses with complementary strengths and capabilities will enable full vertical integration across the biosimilars value chain, leading to operational and financial efficiencies, helping us maximize value from our biosimilars portfolio.

Under a Transition Services Agreement, Viartis will provide commercialization services and certain transition services to Biocon Biologics for an expected two-year period.

Full ownership of its current partnered biosimilar assets with Viartis will create a strong portfolio of biosimilars. This, along with a direct global commercial presence and value accretive revenues and profits, positions BBL to better leverage the evolving market dynamics.

Deal Financing

The cash payment of USD 2 billion is to be funded by ~USD 800 million raised through equity infusion in BBL and the remainder to be funded by debt, additional equity or a combination thereof.

BBL has received firm commitment from financial institutions for debt financing. The debt assumed in this transaction will be supported by larger EBITDA base, as an outcome of the combination of BBL-Viartis business, vaccines income streams, and future equity infusion in BBL.

NOVEL BIOLOGICS

Equillum, our U.S. based partner has initiated a Phase 3 EQUATOR study of Itolizumab in patients with acute graft-versus-host disease (aGVHD). The randomized, double-blind study will assess the efficacy and safety of itolizumab versus placebo as a first-line therapy for aGVHD in combination with corticosteroids. The primary objective of the study is to achieve early disease response, with key secondary objectives to evaluate durability of response, corticosteroid use, survival outcomes, and chronic GVHD incidence.

RESEARCH SERVICES: Syngene

Q4FY22

- **Q4FY22 revenue at Rs 758 Crore, up 15% YoY**
- **Q4FY22 PBT at Rs 179 Crore, up 14% YoY**

FULL YEAR FY22

- **FY22 revenue at Rs 2,604 Crore, up 19% YoY**

Commenting on the performance, **Jonathan Hunt, CEO & Managing Director, Syngene** said: *"I am pleased with the strong finish we had to the year and that we delivered results at the high end of our upgraded guidance range."*

Reflecting on the last two years of the pandemic, I am extremely proud of our track record: we created more than 2000 new jobs – more than in any other two-year period of the company's history - and gained more than 100 new clients in the last year. We also extended and expanded our long-term partnership with Amgen Inc. and continued to invest in new capacity and technology to underpin future growth.

Looking ahead, we see growing demand for research, development and manufacturing services around the world and we are well-positioned to take advantage of these new opportunities.”

Business Performance

Q4 growth was driven by solid delivery across all divisions, with a strong performance by Development Services.

Completed phase three of the Hyderabad research facility expansion plan, with 600 scientists accommodated and a further expansion being planned.

Enclosed: Fact Sheet – with Financials as per IND-AS

About Biocon Limited:

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. **Website: www.biocon.com; Follow-us on Twitter: [@bioconlimited](https://twitter.com/bioconlimited)** for company updates.

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., is a unique, fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower costs of biologics therapies while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology and other non-communicable diseases. Seven molecules from Biocon Biologics' portfolio have been commercialized in key emerging markets and developed markets like U.S., EU, Australia, Canada, Japan. It has many firsts to its credit including the most recent U.S. FDA approval of the world's first interchangeable biosimilar, awarded to its Insulin Glargine, which has been commercialized in the U.S. in 2021. Biocon Biologics has signed a strategic alliance with Serum Institute Life Sciences (subject to certain closing conditions) to address the inequitable access to life saving vaccines and biologics globally. With a team of ~5,000 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients' worldwide. **Website: www.bioconbiologics.com; Follow us on Twitter: [@BioconBiologics](https://twitter.com/BioconBiologics)** for company updates.

FOR MORE INFORMATION	
MEDIA	INVESTOR
Biocon Group & Biocon Biologics Seema Ahuja Global Head of Communications & Corporate Brand +91 80 2808 2222 +91 99723 17792 ✉ seema.ahuja@biocon.com	Biocon Limited Aishwarya Sitharam Head - Investor Relations +91 80 2808 2083 +91 93236 48143 ✉ aishwarya.sitharam@biocon.com
Biocon Limited Calvin Printer Head - Corporate Communications +91 80 2808 2132 +91 70329 69537 ✉ calvin.printer@biocon.com	Biocon Biologics Nikunj Mall Head - Investor Relations +91 998 777 4078 ✉ nikunj.mall@biocon.com

Earnings Call

The management of the Company will host an Earnings Call on 29th April, 2022 at 9:00 hrs, over a Zoom Webinar, where the senior management will discuss the company's performance and answer questions from participants. Details of the Zoom webinar are given below as well as on the company website www.biocon.com under Investors>>Financial Calendar>>Earnings Call for period ended December 31, 2021. Transcript of the conference call will be uploaded on the company website in due course.

Zoom Webinar Details	
Date	29 th April, 2022
Time	9:00hrs -10:30hrs IST
Join Zoom Webinar	https://bit.ly/39bTN19 to attend earnings call

Or Copy this URL in your browser: <link>

Forward-Looking Statements: Biocon

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

BIOCON GROUP

FACT SHEET

March - 2022

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			
(Rs. Crores)			
Particulars	Q4'FY 22	Q4'FY 21	Variance %
<u>INCOME</u>			
Generics	717	570	26%
Biosimilars	982	664	48%
Novel Biologics	12	11	17%
Research services	758	659	15%
Inter-segment	(61)	(61)	0%
Revenue from operations #	2,409	1,842	31%
Other income	67	205	-67%
TOTAL REVENUE	2,476	2,048	21%
<u>EXPENDITURE</u>			
Material & Power costs	911	647	41%
Staff costs	428	414	3%
Research & Development expenses*	191	127	50%
Other expenses	288	218	32%
Manufacturing, staff & other expenses	1,817	1,406	29%
EBITDA	659	641	3%
Interest & Finance charges	11	34	-69%
Depreciation & Amortisation	212	184	15%
Share of loss / (profit) in JV / Associate, net	53	70	100%
PBT BEFORE EXCEPTIONAL ITEM	384	353	9%
Exceptional item	(41)	13	-
PBT	343	366	-6%
Taxes	76	60	26%
Taxes on exceptional item	(17)	10	-276%
NET PROFIT BEFORE MINORITY INTEREST	284	296	-4%
Minority interest	46	36	25%
Minority interest on exceptional item	(0)	7	-
NET PROFIT FOR THE PERIOD	239	253	-6%
EPS Rs.	2.0	2.1	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	262	257	2%
Exceptional item, net of taxes	(24)	(4)	526%
NET PROFIT FOR THE PERIOD	239	253	-6%
<i># Licensing Income</i>	9	8	
<i>* Gross Research & Development expenses</i>	232	136	

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q4' FY 22	Q3' FY 22	Variance %
INCOME			
Generics	717	607	18%
Biosimilars	982	981	0%
Novel Biologics	12	16	-21%
Research services	758	641	18%
Inter-segment	(61)	(72)	-15%
Revenue from operations #	2,409	2,174	11%
Other income	67	48	39%
TOTAL REVENUE	2,476	2,223	11%
EXPENDITURE			
Material & Power costs	911	798	14%
Staff costs	428	450	-5%
Research & Development expenses*	191	138	38%
Other expenses	288	300	-4%
Manufacturing, staff & other expenses	1,817	1,686	8%
EBITDA	659	537	23%
Interest & Finance charges	11	15	-29%
Depreciation & Amortisation	212	206	3%
Share of loss / (profit) in JV / Associate, net	53	47	100%
PBT BEFORE EXCEPTIONAL ITEM	384	269	43%
Exceptional item, Net	(41)	-	-100%
PBT	343	269	27%
Taxes	76	49	53%
Taxes on exceptional item	(17)	-	0%
NET PROFIT BEFORE MINORITY INTEREST	284	220	29%
Minority interest	46	33	40%
Minority interest on exceptional item	(0)	-	-
NET PROFIT FOR THE PERIOD	239	187	28%
EPS Rs.	2.0	1.6	
NET PROFIT BEFORE EXCEPTIONAL ITEM	262	187	40%
Exceptional item, net of taxes	(24)	-	
NET PROFIT FOR THE PERIOD	239	187	28%
# Licensing Income	9	17	
* Gross Research & Development expenses	232	178	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	FY 22	FY 21	Variance %
INCOME			
Generics	2,341	2,363	-1%
Biosimilars	3,464	2,800	24%
Novel Biologics	51	11	386%
Research services	2,604	2,184	19%
Inter-segment	(276)	(215)	29%
Revenue from operations #	8,184	7,143	15%
Other income	213	255	-16%
TOTAL REVENUE	8,397	7,398	14%
EXPENDITURE			
Material & Power costs	3,035	2,514	21%
Staff costs	1,710	1,566	9%
Research & Development expenses*	595	553	8%
Other expenses	874	858	2%
Manufacturing, staff & other expenses	6,214	5,490	13%
EBITDA	2,183	1,907	14%
Interest & Finance charges	68	58	17%
Depreciation & Amortisation	814	715	14%
Share of loss / (profit) in JV / Associate, net	207	79	100%
PBT BEFORE EXCEPTIONAL ITEM	1,094	1,055	4%
Exceptional item, Net	(111)	13	-
PBT	983	1,068	-8%
Taxes	241	212	14%
Taxes on exceptional item	(29)	10	-404%
NET PROFIT BEFORE MINORITY INTEREST	772	846	-9%
Minority interest	132	99	33%
Minority interest on exceptional item	(8)	7	-
NET PROFIT FOR THE PERIOD	648	740	-12%
EPS Rs.	5.4	6.2	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	722	744	-3%
Exceptional item, net of taxes	(74)	(4)	
NET PROFIT FOR THE PERIOD	648	740	-12%
# Licensing Income	49	40	
* Gross Research & Development expenses	711	627	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	March 31, 2022	March 31, 2021
ASSETS		
Non-current assets		
(a) Property, plant and equipment	5,677	5,557
(b) Capital work-in-progress	3,420	2,254
(c) Right-of-use assets	267	153
(d) Goodwill	26	26
(e) Other intangible assets	599	627
(f) Intangible assets under development	690	547
(g) Investment in associates and a joint venture	8	180
(h) Financial assets		
Investments	362	564
Derivative assets	147	66
Other financial assets	45	201
(i) Income tax asset, net	314	265
(j) Deferred tax asset, net	293	308
(k) Other non-current assets	163	176
Non-current assets	12,012	10,922
Current assets		
(a) Inventories	2,298	1,867
(b) Financial assets		
Investments	1,218	1,209
Trade receivables	2,058	1,503
Cash and cash equivalents	663	953
Other bank balances	1,085	1,062
Derivative assets	122	83
Loans and advances	67	-
Other financial assets	451	507
(c) Other current assets	421	364
(c) Assets held for sale	-	52
Current assets	8,382	7,600
TOTAL - ASSETS	20,394	18,522
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	7,832	7,027
Equity attributable to owners of the Company	8,433	7,627
Non-controlling interests	1,038	881
Total Equity	9,471	8,508
Non-current liabilities		
(a) Financial liabilities		
Borrowings	3,999	2,962
Lease liabilities	222	114
Derivative liabilities	14	62
Other financial liabilities	1,503	1,503
(b) Provisions	92	106
(c) Deferred tax liability, net	52	32
(d) Other non-current liabilities	1,215	1,025
Non-current liabilities	7,096	5,805
Current liabilities		
(a) Financial liabilities		
Borrowings	906	1,397
Lease liabilities	21	8
Trade payables	1,609	1,514
Derivative liabilities	12	26
Other financial liabilities	363	382
(b) Provisions	131	109
(c) Income tax liability, net	162	152
(d) Other current liabilities	625	581
(e) Liabilities classified as held for sale	-	40
Current liabilities	3,827	4,210
TOTAL - EQUITY AND LIABILITIES	20,394	18,522